SITC 2024 preview – duelling TIGIT duds
Failed trials of vibostolimab and domvanalimab will be unveiled at SITC late-breakers.
Essa terminates an N-terminal journey
After beating "historical" Xtandi masofaniten fails to beat actual Xtandi.
FDA red and green lights: October 2024
October's US approvals included Scemblix, Vyloy and Itovebi, while Lumakras was delayed.
No SOS for Bayer's SOS1
The group goes after a KRAS-related target on which Boehringer recently gave up.
The month ahead: November’s upcoming events
Conferences ramp up, and ASH abstracts near.
